Anti-FcRn antibodies and methods for treating myasthenia gravis

A method of treating myasthenia gravis (MG) in a patient in need thereof comprising:

• intravenously administering an initial loading dose of about 30 mg/kg of an anti-FcRn antibody followed by intravenously administering a maintenance dose of about 15 mg/kg of the anti-FcRn antibody;
• and
• measuring levels of total cholesterol or calculated low-density lipoprotein (LDL) in the patient;
• wherein the anti-FcRn antibody comprises:
• a heavy chain comprising a HCDR1 of SEQ ID NO:
• 6, a HCDR2 of SEQ ID NO:
• 7, and a HCDR3 of SEQ ID NO:
• 8;
• and
• a light chain comprising a LCDR1 of SEQ ID NO:
• 3, a LCDR2 of SEQ ID NO:
• 4, and a LCDR3 of SEQ ID NO:
• 5;
• wherein the initial loading dose is administered as a single dose;
• wherein the maintenance dose is administered 2 weeks after the administration of the initial loading dose and every 2 weeks thereafter;
• wherein the patient achieves at least 3 points reduction from baseline in MG activity of daily living profile (MG-ADL) score and at least 4 points reduction from baseline in quantitative MG (QMG) score following said administration of the anti-FcRn antibody by 24 weeks from the initial loading dose;
• wherein an increase in levels of total cholesterol or low-density lipoprotein (LDL) in the patient as compared to the levels prior to the administration of the anti-FcRn antibody is at most by 24 weeks 10% from the initial loading dose.